A detailed history of Erste Asset Management Gmb H transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Erste Asset Management Gmb H holds 689,935 shares of BMRN stock, worth $45.2 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
689,935
Holding current value
$45.2 Million
% of portfolio
0.58%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$69.02 - $93.84 $47.6 Million - $64.7 Million
689,935 New
689,935 $48.5 Billion
Q2 2024

Nov 26, 2024

BUY
$74.43 - $92.22 $5.95 Million - $7.38 Million
80,000 Added 13.03%
694,125 $57.3 Billion
Q1 2024

Nov 26, 2024

SELL
$83.81 - $99.0 $1.68 Million - $1.98 Million
-20,000 Reduced 3.15%
614,125 $53.8 Billion
Q4 2023

Nov 26, 2024

BUY
$76.22 - $98.51 $1.98 Million - $2.56 Million
26,000 Added 4.28%
634,125 $61.2 Billion
Q3 2023

Nov 26, 2024

BUY
$85.07 - $94.48 $7.99 Million - $8.87 Million
93,911 Added 18.26%
608,125 $53.9 Billion
Q2 2023

Nov 26, 2024

BUY
$86.68 - $100.3 $30,164 - $34,904
348 Added 0.06%
589,592 $51.3 Billion
Q1 2023

Nov 26, 2024

BUY
$87.74 - $117.27 $6.49 Million - $8.68 Million
74,010 Added 14.36%
589,244 $57.1 Billion
Q4 2022

Nov 26, 2024

BUY
$80.93 - $108.63 $238,257 - $319,806
2,944 Added 0.58%
514,214 $53.1 Billion
Q3 2022

Nov 26, 2024

SELL
$82.16 - $96.94 $14.4 Million - $16.9 Million
-174,701 Reduced 25.32%
515,234 $43.7 Billion
Q2 2022

Nov 26, 2024

BUY
$71.48 - $86.85 $11.4 Million - $13.8 Million
159,430 Added 45.31%
511,270 $42.5 Billion
Q1 2022

Nov 22, 2024

SELL
$74.28 - $92.69 $3.47 Million - $4.32 Million
-46,650 Reduced 7.67%
561,650 $43.4 Billion
Q4 2021

Nov 22, 2024

SELL
$71.72 - $91.47 $5.85 Million - $7.47 Million
-81,635 Reduced 11.83%
608,300 $54.2 Billion
Q3 2021

Nov 22, 2024

BUY
$74.77 - $85.47 $254,218 - $290,598
3,400 Added 0.56%
608,300 $47 Billion
Q1 2021

Nov 22, 2024

BUY
$74.73 - $90.69 $5.33 Million - $6.47 Million
71,360 Added 13.37%
604,900 $45.6 Billion
Q4 2020

Nov 22, 2024

BUY
$72.61 - $90.2 $5.14 Million - $6.39 Million
70,800 Added 15.3%
533,540 $46.3 Billion
Q3 2020

Nov 22, 2024

SELL
$71.87 - $131.03 $16.3 Million - $29.8 Million
-227,195 Reduced 32.93%
462,740 $35.2 Billion
Q2 2020

Nov 22, 2024

BUY
$79.55 - $124.22 $3.95 Million - $6.17 Million
49,640 Added 15.12%
377,840 $46.5 Billion
Q1 2020

Nov 22, 2024

SELL
$71.37 - $96.85 $7.97 Million - $10.8 Million
-111,700 Reduced 25.39%
328,200 $27.5 Billion
Q4 2019

Nov 22, 2024

SELL
$64.27 - $86.37 $16.1 Million - $21.6 Million
-250,035 Reduced 36.24%
439,900 $37.3 Billion
Q3 2019

Nov 22, 2024

BUY
$67.4 - $85.11 $102,448 - $129,367
1,520 Added 0.37%
407,800 $27.6 Billion
Q2 2019

Nov 22, 2024

BUY
$80.35 - $93.9 $4.36 Million - $5.1 Million
54,300 Added 15.43%
406,280 $34.6 Billion
Q1 2019

Nov 22, 2024

SELL
$84.2 - $98.62 $28.5 Million - $33.3 Million
-337,955 Reduced 48.98%
351,980 $31.2 Billion
Q4 2018

Nov 26, 2024

SELL
$80.14 - $106.07 $27.1 Million - $35.9 Million
-338,095 Reduced 49.0%
351,840 $29.4 Billion

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.